Targeting NAD+ regeneration enhances antibiotic susceptibility of Streptococcus pneumoniae during invasive disease
Fig 6
Fomepizole enhances erythromycin susceptibility in multidrug-resistant Spn pneumonia and invasive disease.
The potential of fomepizole as an adjuvant was tested in a pneumonia model using multidrug-resistant Spn serotype 35B. (A) Infection was done intratracheally, with erythromycin and fomepizole injected intraperitoneally 18 hours post-infection. At 48 hours post-infection, animals were killed, and the bacterial burden in the (B) lungs, (C) spleen, and (D) heart were determined (n ≥ 8). Statistical analyses were done using a Kruskal–Wallis ANOVA test with Dunnett post hoc test with control group. Asterisks indicate statistical significance: *, P ≤ 0.05, **, P ≤ 0.01; ***, P ≤ 0.001.